Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Biora Therapeutics
(NASDAQ:BIOR)
Intraday
$0.6392
0.0115
[1.83%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$0.6392
0.0115
[1.83%]
Last update: 11:43AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Biora Therapeutics Stock (NASDAQ:BIOR)
Biora Therapeutics Stock (NASDAQ: BIOR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, April 18, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Apr 18, 2024, 4:31PM
Monday, April 08, 2024
Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Benzinga Newsdesk
-
Apr 8, 2024, 8:02AM
Thursday, April 04, 2024
Biora Therapeutics Achieves Interim Results For Clinical Trial Of BT-600, Advancing NaviCap Platform Development
Benzinga Newsdesk
-
Apr 4, 2024, 8:04AM
Monday, April 01, 2024
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Avi Kapoor
-
Apr 1, 2024, 2:31PM
Biora Therapeutics shares are trading lower after the company announced a $6 million registered direct offering of 5,454,548 shares of common stock at a price of $1.10 per share.
Benzinga Newsdesk
-
Apr 1, 2024, 1:23PM
Earlier Biora Therapeutics Announced A $6M Registered Direct Offering Of 5,454,548 Shares Of Common Stock At A Price Of $1.10 Per Share
Benzinga Newsdesk
-
Apr 1, 2024, 1:19PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
Apr 1, 2024, 12:31PM
Wednesday, March 27, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Mar 27, 2024, 4:31PM
Tuesday, March 26, 2024
Biora Therapeutics: Q4 Earnings Insights
Benzinga Insights
-
Mar 26, 2024, 4:45PM
Biora Therapeutics Q4 EPS $(0.63) Misses $(0.59) Estimate
Benzinga Newsdesk
-
Mar 26, 2024, 4:42PM
Earnings Scheduled For March 26, 2024
Benzinga Insights
-
Mar 26, 2024, 4:47AM
Monday, March 25, 2024
Earnings Outlook For Biora Therapeutics
Benzinga Insights
-
Mar 25, 2024, 11:01AM
Monday, March 11, 2024
Biora Therapeutics Further Reduces Net Debt, Convertible Notes Exchange Brings In Another $2.8M In New Capital And Announces Monetization Of Legacy Asset Brings In $3M In Nondilutive Capital
Benzinga Newsdesk
-
Mar 11, 2024, 8:02AM
Tuesday, February 27, 2024
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Feb 27, 2024, 1:18PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Feb 27, 2024, 12:31PM
Monday, February 26, 2024
Biora Therapeutics Announces Completion Of Single-Ascending Dose Cohorts Of Phase 1 Clinical Study Of BT-600
Benzinga Newsdesk
-
Feb 26, 2024, 8:05AM
Monday, February 05, 2024
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Feb 5, 2024, 8:04AM
Friday, January 19, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Jan 19, 2024, 4:31PM
Wednesday, January 17, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Jan 17, 2024, 4:31PM
Tuesday, January 16, 2024
Biora Therapeutics Provides Guidance On Anticipated Milestones During 2024; Says We Begin 2024 In The Clinic With Our Phase 1 Study For BT-600, Which Will Be A Major De-Risking Step In The Development Of Our NaviCap Platform
Benzinga Newsdesk
-
Jan 16, 2024, 8:02AM
Monday, January 08, 2024
Biora Therapeutics Announces Initiation Of Phase 1 Clinical Study Of BT-600; First-In-Human Trial Of BT-600 Drug-Device Combination, Following Multiple Successful Device-only Human Studies
Benzinga Newsdesk
-
Jan 8, 2024, 8:19AM
Friday, January 05, 2024
Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
-
Jan 5, 2024, 8:03AM
Wednesday, January 03, 2024
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Jan 3, 2024, 4:31PM
Tuesday, January 02, 2024
HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $50 Price Target
Benzinga Newsdesk
-
Jan 2, 2024, 12:11PM
Biora Therapeutics Progresses Research Collaboration For The BioJet Systemic Oral Delivery Platform; Met Key Performance Milestones As Part Of Its Research Collaboration With AstraZeneca
Benzinga Newsdesk
-
Jan 2, 2024, 8:09AM
Tuesday, December 19, 2023
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Dec 19, 2023, 4:31PM
Biora Therapeutics Announces New Patent For Its NaviCap Targeted Oral Delivery Platform
Benzinga Newsdesk
-
Dec 19, 2023, 8:12AM
Monday, December 18, 2023
Biora Therapeutics Agrees With Institutional Investors Athyrium Capital Management, Davidson Kempner Capital Management, And Highbridge Capital Management To Reduce Its Net Debt By 60% Through A Convertible Note Exchange Which Brings $16.7M In New Capital
Benzinga Newsdesk
-
Dec 18, 2023, 8:04AM
Monday, December 11, 2023
Biora Therapeutics Collaborates With Large Pharmaceutical Company To Test BioJet Systemic Oral Delivery Platform's Ability To Achieve Bioavailability Through Oral Delivery Of The Undisclosed Collaborator's Molecules To The Small Intestine In Animal Models
Benzinga Newsdesk
-
Dec 11, 2023, 8:11AM
Friday, December 01, 2023
Why Genesco Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Dec 1, 2023, 12:04PM
Why Is Chronic Disease Focused Biora Therapeutics Stock Trading Higher Today?
Vandana Singh
-
Dec 1, 2023, 10:01AM
Why UiPath Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Dec 1, 2023, 8:30AM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
Dec 1, 2023, 8:06AM
Thursday, November 30, 2023
Biora Therapeutics Secures FDA Clearance Of IND Application For Drug/Device Combination BT-600 Targeting Treatment Of Ulcerative Colitis
Benzinga Newsdesk
-
Nov 30, 2023, 4:49PM
Thursday, November 16, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Nov 16, 2023, 4:31PM
Monday, November 13, 2023
Recap: Biora Therapeutics Q3 Earnings
Benzinga Insights
-
Nov 13, 2023, 4:40PM
Biora Therapeutics Q3 EPS $(0.75) Beats $(0.76) Estimate
Benzinga Newsdesk
-
Nov 13, 2023, 4:38PM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights
-
Nov 13, 2023, 8:06AM
Earnings Scheduled For November 13, 2023
Benzinga Insights
-
Nov 13, 2023, 6:40AM
Friday, November 10, 2023
Earnings Outlook For Biora Therapeutics
Benzinga Insights
-
Nov 10, 2023, 12:02PM
Monday, October 30, 2023
Biora Therapeutics Submits Updated IND Application For BT-600; Update Includes Supplemental Information And Provides Additional Time To Complete Regulatory Review; Biora Anticipates Remaining On Track With Its Phase 1 Clinical Trial Execution Timeline
Benzinga Newsdesk
-
Oct 30, 2023, 4:56PM
Monday, October 23, 2023
Biora Therapeutics Plans To Submit Updated IND Application For BT-600; Says FDA Requested Additional Information On IND For BT-600
Benzinga Newsdesk
-
Oct 23, 2023, 5:32PM
Wednesday, October 11, 2023
On October 10, Biora Therapeutics Issued A Warrant To Purchase Up To 1M Shares, With An Exercise Price Of $1.93, To An Investor In A Private Placement Transaction - 8K
Benzinga Newsdesk
-
Oct 11, 2023, 6:53AM
Tuesday, October 10, 2023
Biora Therapeutics Said Effective As Of October 9, 2023, The Maximum Aggregate Offering Price Of The Of The ATM Facility Is $37,600,000
Charles Gross
-
Oct 10, 2023, 6:53AM
Monday, October 02, 2023
HC Wainwright & Co. Maintains Buy Rating for Biora Therapeutics: Here's What You Need To Know
Benzinga Insights
-
Oct 2, 2023, 1:00PM
HC Wainwright & Co. Maintains Buy on Biora Therapeutics, Lowers Price Target to $50
Benzinga Newsdesk
-
Oct 2, 2023, 7:01AM
Monday, September 25, 2023
Biora Therapeutics Reports Submission Of IND Application To US FDA For BT-600 Program
Benzinga Newsdesk
-
Sep 25, 2023, 8:01AM
Tuesday, September 19, 2023
Biora Therapeutics Enhances Financial Position Through $50M Equity Swap Agreement with Athyrium Capital
Benzinga Newsdesk
-
Sep 19, 2023, 8:09AM
Tuesday, September 05, 2023
Biora Therapeutics Announced The Achievement Of Its Device Performance Targets For Its BioJet Platform, Which Uses An Ingestible Device To Achieve Systemic Uptake Through Liquid Jet Delivery To The Small Intestine
Benzinga Newsdesk
-
Sep 5, 2023, 8:08AM
Monday, September 04, 2023
Robot Pills: A Game-Changer In Drug Delivery, With Potential Stock Upside
Benzinga Neuro
-
Sep 4, 2023, 5:17AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch